This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST HIGH

Nortadalafil

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST HIGH

Nortadalafil has no upside over the FDA-approved parent (tadalafil) for any user with legitimate access. Tadalafil generic is $0.30-0.80 per 20mg pill via the same Indian pharmacies that sell modafinil — same gray-market sourcing reality, but with 20+ years of safety data, validated PK, and FDA-grade purity. Nortadalafil's only purchase is "research-chem-only sourcing" framing — i.e., scenarios where you genuinely cannot get tadalafil. For a 20yo with telehealth access AND existing Indian-pharmacy supplier relationships, that scenario is hypothetical. Stays on watch-list because the class itself is interesting (the cognitive-flow / vascular hedge is real for tadalafil) and because nortadalafil shows up as an adulterant in counterfeit "natural male enhancement" products — worth knowing how to recognize and avoid. Verdict would change to SKIP-ALWAYS only if FDA escalated to schedule it; would never change to OPTIONAL-ADD because the cleaner alternative dominates.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload (this archetype)
    WATCH-LIST

    Tadalafil dominates on every axis. The only "value" of nortadalafil literacy is recognizing it on FDA recall lists.

  • 30-50, executive maintenance
    WATCH-LIST

    Same reasoning. Tadalafil daily 2.5-5 mg is the actual play here.

  • 50+, mild cognitive decline
    WATCH-LIST

    The dementia-incidence observational signal is for tadalafil/sildenafil, not nortadalafil. Use the validated parent compound.

  • Anxiety-prone
    WATCH-LIST

    Class is neutral on anxiety; no reason to introduce purity uncertainty.

  • High athletic load, tested status
    WATCH-LIST

    PDE5i are not currently WADA-banned, but counterfeit supplements often co-contain banned anabolics — purity uncertainty is the issue.

  • Sleep-disordered
    WATCH-LIST

    Class doesn't affect sleep architecture.

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST
  • Strength/anabolic-focused
    WATCH-LIST
  • Curious about the cognitive-flow / vascular hedge
    U

    tadalafil daily 2.5 mg, not nortadalafil. The case for the class is the case for tadalafil specifically.

▸ Subjective experience (deep)

(All from gray-market RC-vendor reports — extremely low-confidence, no controlled trial data.)

  • Onset: ~30-60 min oral (faster than tadalafil per gray-market reports — consistent with the more polar / more rapidly absorbed structural argument)
  • Peak: ~1-3 hr
  • Plateau: ~4-6 hr (much shorter than tadalafil's 24-36 hr "weekend pill" plateau)
  • Taper: trails out by ~10-12 hr
  • Characteristic effects (claimed): vasodilation feel, easier erection, mild headache and flushing similar to tadalafil at equivalent doses. Some users report it "feels weaker" — which is consistent with the ~half-potency in vitro IC50.
  • Side effect spread (claimed): similar profile to tadalafil but compressed into shorter time window. The fundamental class side-effects (headache, back pain, dyspepsia, NAION risk, priapism risk) all plausibly carry over.

The lack of validated clinical reports means none of this should be weighted heavily.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown for nortadalafil specifically; tadalafil shows minimal receptor downregulation in years of daily dosing, and the class is generally tolerance-stable.
  • Recommended cycle: N/A — not recommended.
  • Reset protocol: N/A.
▸ Stacking deep dive

Synergistic with

N/A — do not use, but if used, the synergy/conflict map mirrors tadalafil:

  • L-citrulline / L-arginine (NO precursors): theoretical additive
  • Methylene blue, citicoline, agmatine: mild theoretical additives via NO/cGMP nodes
  • Beta-alanine, taurine, creatine: pharmacologically neutral

Avoid stacking with (class-wide hard contraindications)

  • Nitrates of any form (nitroglycerin, isosorbide, "poppers"/amyl nitrite) — ABSOLUTE CONTRAINDICATION. Severe, potentially fatal hypotension. This is the headline FDA warning for every nortadalafil supplement recall.
  • Alpha-blockers (tamsulosin, doxazosin, terazosin) — additive hypotension
  • Riociguat / sGC stimulators — contraindicated; redundant pathway hit
  • Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit) — assumed AUC raise, but unmeasured for nortadalafil specifically
  • Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) — assumed exposure drop

Neutral / safe co-administration

Unknown — no human interaction data.

▸ Drug interactions deep dive

Assumed CYP3A4 substrate by structural analogy to tadalafil. No formal interaction studies exist. The FDA safety messaging treats nortadalafil as functionally equivalent to tadalafil for nitrate-interaction risk — which is the only interaction warning that survives the "no human data" caveat because the mechanism is so direct.

▸ Pharmacogenomics

Unknown for nortadalafil specifically. CYP3A4/5 polymorphisms presumably matter (slow metabolizers higher AUC; ultrarapid lower) but no PGx data has been generated. NOS3 (eNOS) baseline NO production presumably modulates response magnitude as it does for tadalafil.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research chemical Kimera Chems, ApexBio, MedChemExpress $30-80 / 1 g Low "Not for human consumption" disclaimer; COA inconsistent across vendors and lots
Adulterated supplement (unintentional purchase) Various sketchy Amazon / direct-to-consumer $20-60 / bottle Zero The most common real-world exposure pathway; the user does not know he is consuming nortadalafil. FDA recalls examples: Sustain, Schwinnng, Arize, Endurea, MR.7 SUPER 700000, Vitality
Tadalafil generic (the dominant strategy instead) Indian pharmacy (AllDayChemist, ReliableRX, BuyModa, AfinilExpress) — same vendors he uses for modafinil $0.30-0.80/pill 20mg Medium-high Same gray-market sourcing reality as nortadalafil, but with FDA-validated active ingredient and 20+ years of safety data
Tadalafil generic (US legitimate) Hims, Roman, Mark Cuban Cost Plus, GoodRx + local pharmacy $10-20/mo High Telehealth Rx pathway is trivial for ED indication

The user-archetype lesson: there is no realistic sourcing scenario in which nortadalafil is preferable. Tadalafil is the cleaner product at the same price across both gray-market and legitimate paths.

▸ Biomarkers to track (deep)
  • N/A — not recommended for use. If used despite recommendation, the class-wide tadalafil monitoring panel applies:
    • Baseline: resting BP (3-day average), HR, lipid panel, hsCRP, liver panel, baseline visual acuity
    • During use: resting + orthostatic BP, headache frequency, back/myalgia tracking, vision symptoms
    • Stop signs: any sudden vision change → ophthalmology immediately; priapism → ER
▸ Controversies / open debates Live debate
  • Is there any legitimate use case for nortadalafil? Not for anyone with telehealth or established gray-market tadalafil access. The hypothetical case ("a researcher in a jurisdiction where tadalafil is unavailable but nortadalafil somehow is") is so narrow it doesn't apply to a US-based user.
  • Will FDA escalate nortadalafil to scheduled-drug status? Plausible — the agency has done this with sibutramine analogs and cathinone analogs after enough enforcement actions. As of 2026, nortadalafil is still treated as an "undeclared drug ingredient" rather than a separately scheduled compound.
  • Why does it keep showing up in supplements? Patent-evasion and analytical-detection-evasion. The original nortadalafil scaffold gets caught by FDA labs, so clandestine chemists iterate to N-cyclohexyl-, N-cyclopentyl-, 2-hydroxypropyl- variants. Liu 2023 and Xu 2016 are essentially the analytical-arms-race front line.
  • Half-life: 6 hours or longer? The widely cited ~6 hr figure comes from limited animal-PK and chemistry-vendor literature; one credible-but-not-registrational dataset suggests it could trend longer at lower doses. Net: not nailed down, and probably never will be without a registrational program no one will fund.
▸ Verdict change log
  • 2026-05-10 — Initial verdict: WATCH-LIST, HIGH confidence. Rationale: the FDA-approved parent compound (tadalafil) is dominant on price, purity, PK validation, and safety data; nortadalafil's only role on this user's stack is "things to recognize and avoid" in adulterated-supplement screening.
▸ Open questions / gaps Open
  • Will any analytical chemistry group publish a definitive human-PK study on nortadalafil? Unlikely without a regulatory mandate.
  • Selectivity panel against PDE6, PDE11 — would clarify whether nortadalafil's side effect profile differs from tadalafil's. Probably never measured rigorously.
  • FDA enforcement trajectory — escalation to scheduled status would fully close the WATCH-LIST verdict to SKIP-ALWAYS.
  • New variants in the wild — N-cyclohexyl, N-cyclopentyl, 2-hydroxypropyl already documented; the next wave (N-allyl, N-fluoroethyl, etc.) is predictable from medicinal-chemistry priors.

References

Liu et al. 2023 — Isolation and characterization of a novel tadalafil analogue adulterant, N-cyclohexyl nortadalafil, in a dietary supplement (J Pharm Biomed Anal, PMID 36841095)

pubmed.ncbi.nlm.nih.gov · 2023

analytical-chemistry detection of designer-adulterant nortadalafil variants

View Study

Xu et al. 2016 — Isolation and characterization of a tadalafil analogue, N-cyclopentyl nortadalafil in health supplement (J Pharm Biomed Anal, PMID 26580820)

pubmed.ncbi.nlm.nih.gov · 2016

earlier designer-adulterant characterization

View Study

Jin et al. 2024 — UPLC-MS/MS-Based Target Screening of 90 PDE5 Inhibitors in 5 Dietary Supplements (Molecules, PMID 39125006)

pmc.ncbi.nlm.nih.gov · 2024

detected 2-hydroxypropyl nortadalafil in nutritional wine; broad screening framework

View Study

Li, Xu, Moezzi 2021 — Identification of Erectile Dysfunction Drugs in Dietary Supplements by LC Ion Trap MS (J Diet Suppl, PMID 32351143)

pubmed.ncbi.nlm.nih.gov · 2021

LC-MS detection methodology including nortadalafil class

View Study

Tucker et al. 2018 — Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With FDA Warnings (JAMA Network Open, PMID 30646238)

pmc.ncbi.nlm.nih.gov · 2018

776 contaminated supplements 2007-2016, sexual-enhancement category dominant

View Study

FDA — Today The World Recalls Sustain and Schwinnng (Feb 2024) — undeclared tadalafil + nortadalafil

fda.gov · 2024
View Source

FDA — Today The World Recalls Arize Herbal (Feb 2024) — undeclared nortadalafil

fda.gov · 2024
View Source

FDA — Arize contains hidden drug ingredient (consumer alert)

fda.gov
View Source

FDA — ENDUREA contains hidden drug ingredients (consumer alert)

fda.gov
View Source

Tadalafil prescribing information (FDA label, Cialis)

accessdata.fda.gov

class PK / safety reference for the parent compound

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…